Present Performance: InflaRx N.V. (NASDAQ: IFRX)

InflaRx N.V. is part of the biotechnology industry and trades as part of the healthcare sector. The company CEO is Niels Riedemann. InflaRx NV is a biopharmaceutical company. It discovers and develops potent and specific inhibitors of the complement activation factor known as C5a.

Previous Intraday Performance:

The IFRX shares had a previous change of -3.27% which opened at 48.50 and closed at 47.02. It moved to an intraday high of 51.33 and a low of 45.93.

SeekingAlpha:  XBiotech: Strong Upside Potential In Atopic Dermatitis And Hidradenitis Suppurativa

Historical Performance:

Over the last five trading days, IFRX shares returned 17.70% and in the past 30 trading days it returned 41.12%. Over three months, it changed 59.93%. In one year it has changed 54.37% and within that year its 52-week high was 51.33 and its 52-week low was 20.31. IFRX stock is 131.51% above its 52 Week Low.

Our calculations result in a 200 day moving average of 32.89 and a 50 day moving average of 35.35. Right now, IFRX stock is trading 42.94% above its 200 day moving average.

SeekingAlpha:  XBiotech: Strong Upside Potential In Atopic Dermatitis And Hidradenitis Suppurativa


The company has a market cap of $1.2b with 25.9m shares outstanding and a float of 25.9m shares. Trading volume was 283,726 shares and has experienced an average volume of 134,645 shares. Our calculation, using the current average volume and close price, leads me to believe that the liquidity is bad, highly speculative and an investor may want to avoid this stock.


The last annual reported EPS for InflaRx N.V. was -3.12 which ended on 31st of December 2017. Based on 5 analyst estimates, the consensus EPS for the next quarter is -0.44.

Below was the last reported quarterly earnings per share:
09-30-2018:  -0.31
06-30-2018:  -0.12
03-31-2018:  -0.49

The next earnings report will be: 04-11-2019

The long-term trend of the EPS is an important number as it indicates the present value of InflaRx N.V..

Indicators Also to Watch:

Based on the latest filings, there is 57.20% of institutional ownership.

I calculated the beta to be -0.85

SeekingAlpha:  Will 90 Champion, Contender, And Challenger Dividend Stars Beat Wall Street Targets?

Fundamental Numbers:

Based on last reported financials, the company’s return on equity is -51.05%, return on assets is -33.13% and price-to-book is 7.08.

Company Score Card:

Results are out of six:
 0  : Growth Expectations Result
 6  : Financial Safety Result
 0  : Past Performance Result
 0  : Valuation Result
 0  : Dividend Safety Result
 1  : Overall Result

Tags: , , ,

Source link

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *